Public Disclosures

DateTitleReporter
24.Mar.2022
Final Clinical Study Report (CSR) of the Phase 3 Study of HD201 (Trastuzumab, Tuznue®)Prestige BioPharma Limited
25.Feb.2022
Half-year Report (FY2022, Q2)Prestige BioPharma Limited
17.Feb.2022
Approval for PBP1510 Clinical Trial (Phase 1/2a) in SpainPrestige BioPharma Limited
28.Jan.2022
Decision on paid-up capital increase of PBP Korea (USD 45 million)Prestige BioPharma Limited
27.Jan.2022
Acquisition of Patent Rights for ‘Antibody specifically binding to PAUF and use thereof’ in Japan
Prestige BioPharma Limited
27.Dec.2021
Results of the Extraordinary General MeetingPrestige BioPharma Limited
17.Dec.2021
Decision to Make an Equity Investment on PBP Korea (USD 90 million)Prestige BioPharma Limited
09.Dec.2021
Notice of the Extraordinary General MeetingPrestige BioPharma Limited
09.Dec.2021
Board Resolution to call the Extraordinary General MeetingPrestige BioPharma Limited
09.Dec.2021
Decision to make a cash loan to Prestige Biologics Co., Ltd. (USD 110 million) Prestige BioPharma Limited
09.Dec.2021
Supply and Commercialization Agreement with Dr. Reddy for HD201 (Trastuzumab biosimilar)Prestige BioPharma Limited
03.Dec.2021
Report on Stocks Held in Bulk / Report on Status of Specific Securities Owned by Executive Officers, etc. Octava Fund Limited
03.Dec.2021
Report on Changes in Equity Shares of the Largest Shareholder Octava Fund Limited
29.Nov.2021
Quarterly Report (FY2022, Q1)Prestige BioPharma Limited
29.Nov.2021
Contract Manufacturing Agreement with Enso and StelisPrestige BioPharma Limited
17.Nov.2021
Other Management Information(Voluntary Disclosure)(Public announcement of the setting of the reference date for the depository receipt for the confirmation of the shareholders of rights at the extraordinary meeting of shareholders)
Prestige BioPharma Limited
15.Nov.2021
Confirmation to Grant Voting Rights as of 30/November/2021 for EGM (Extraordinary General Meeting)
Prestige BioPharma Limited
24.Sep.2021
Appointment or Dismissal of Outside Directors (Reappointment of Prof. Bang Kue Ho)
Prestige BioPharma Limited
24.Sep.2021
Results of the 6th Annual General MeetingPrestige BioPharma Limited
16.Sep.2021
Annual Report (FY2021)Prestige BioPharma Limited
15.Sep.2021
[Correction] Notice of the 6th Annual General Meeting
Prestige BioPharma Limited
15.Sep.2021
[Correction] Board Resolution to call the 6th Annual General MeetingPrestige BioPharma Limited
10.Sep.2021
Submission of Audit Report Prestige BioPharma Limited
9.Sep.2021
[Correction] Decision to Make a Cash Loan to PBP Korea (KRW 61,490 million) - schedule changePrestige BioPharma Limited
12.Aug.2021
Reporting of Sales, Operating income/loss or Net income/loss Changes by 30% or morePrestige BioPharma Limited
12.Aug.2021
[Correction] Quarterly Report (FY2021, Q3)Prestige BioPharma Limited
21.July.2021
Acquisition of patent rights for ‘Method for preparing antibody through regulation of sugar content of antibody’ in EuropePrestige BioPharma Limited
18.June.2021
Approval for PBP1510 clinical trial (Phase 1/2a) in FrancePrestige BioPharma Limited
15.June.2021
Confirmed list of shareholders & voting rights as of 30/June/2021 for shareholders’ meetingPrestige BioPharma Limited
28.May.2021
Decision to make an equity investment on PBP Korea Prestige BioPharma Limited
26.May.2021
Acquisition of patent rights for ‘Antibody specifically binding to PAUF and use thereof’ in USAPrestige BioPharma Limited
24.Feb.2021
Change of KOSPI stock namePrestige BioPharma Limited
18.Feb.2021
Report on status of specific securities owned by executive officersBang Kyuho
16.Feb.2021
Report on stocks held in bulk Octava Fund Limited
16.Feb.2021
Report on status of specific securities owned by executive officersOctava Fund Limited
16.Feb.2021
Report on changes in equity shares of the largest shareholderPrestige BioPharma Limited
15.Feb.2021
Report on status of specific securities owned by executive officersJeon Kyunghee
15.Feb.2021
Report on status of specific securities owned by executive officersMichael Jinwoo Kim
15.Feb.2021
Report on status of specific securities owned by executive officersPark Soyeon
15.Feb.2021
Report on status of specific securities owned by executive officersMayson Partners
15.Feb.2021
Report on stocks held in bulk Mayson Partners
28.Jan.2021
Report on results of issuance of securitiesPrestige BioPharma Limited
22.Jan.2021
ProspectusPrestige BioPharma Limited
22.Jan.2021
Securities registration statement (IPO)Prestige BioPharma Limited